HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco, 11995-073) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, A3160702), penicillin (100 U/ml), and streptomycin (100 μg/ml). Both fibroblasts and LCLs including controls and those from patients with the Pro370Ser and Arg455* variants were prepared as described (12). Breast cancer MCF7 cells were cultured in the above medium. MEFs were prepared and cultured as previously described (12). MEFs from tamoxifen-inducible Brpf1ff;ER-Cre embryos were used to obtain Brpf1-null MEFs after treatment with 0.25 μM 4-hydroxytamoxifen (Sigma-Aldrich, T176) for 3 days in vitro (39). Kat6a-null MEFs were prepared from Kat6af/f;EIIa-Cre embryos as described (57).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.